|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FASTK |
Gene summary for FASTK |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FASTK | Gene ID | 10922 |
| Gene name | Fas activated serine/threonine kinase | |
| Gene Alias | FAST | |
| Cytomap | 7q36.1 | |
| Gene Type | protein-coding | GO ID | GO:0000959 | UniProtAcc | Q14296 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10922 | FASTK | P17T-E | Human | Esophagus | ESCC | 2.94e-13 | 4.68e-01 | 0.1278 |
| 10922 | FASTK | P19T-E | Human | Esophagus | ESCC | 9.90e-11 | 6.88e-01 | 0.1662 |
| 10922 | FASTK | P20T-E | Human | Esophagus | ESCC | 6.34e-38 | 6.22e-01 | 0.1124 |
| 10922 | FASTK | P21T-E | Human | Esophagus | ESCC | 2.78e-53 | 8.96e-01 | 0.1617 |
| 10922 | FASTK | P22T-E | Human | Esophagus | ESCC | 2.73e-27 | 4.51e-01 | 0.1236 |
| 10922 | FASTK | P23T-E | Human | Esophagus | ESCC | 3.32e-25 | 4.97e-01 | 0.108 |
| 10922 | FASTK | P24T-E | Human | Esophagus | ESCC | 1.41e-32 | 5.25e-01 | 0.1287 |
| 10922 | FASTK | P26T-E | Human | Esophagus | ESCC | 8.74e-48 | 7.45e-01 | 0.1276 |
| 10922 | FASTK | P27T-E | Human | Esophagus | ESCC | 2.03e-43 | 7.41e-01 | 0.1055 |
| 10922 | FASTK | P28T-E | Human | Esophagus | ESCC | 5.01e-63 | 1.01e+00 | 0.1149 |
| 10922 | FASTK | P30T-E | Human | Esophagus | ESCC | 1.74e-40 | 9.44e-01 | 0.137 |
| 10922 | FASTK | P31T-E | Human | Esophagus | ESCC | 2.90e-36 | 5.65e-01 | 0.1251 |
| 10922 | FASTK | P32T-E | Human | Esophagus | ESCC | 9.70e-72 | 1.35e+00 | 0.1666 |
| 10922 | FASTK | P36T-E | Human | Esophagus | ESCC | 1.75e-15 | 3.44e-01 | 0.1187 |
| 10922 | FASTK | P37T-E | Human | Esophagus | ESCC | 1.19e-29 | 5.87e-01 | 0.1371 |
| 10922 | FASTK | P38T-E | Human | Esophagus | ESCC | 4.47e-10 | 3.19e-01 | 0.127 |
| 10922 | FASTK | P39T-E | Human | Esophagus | ESCC | 8.11e-28 | 4.63e-01 | 0.0894 |
| 10922 | FASTK | P40T-E | Human | Esophagus | ESCC | 3.27e-20 | 5.13e-01 | 0.109 |
| 10922 | FASTK | P42T-E | Human | Esophagus | ESCC | 2.55e-36 | 7.82e-01 | 0.1175 |
| 10922 | FASTK | P44T-E | Human | Esophagus | ESCC | 6.16e-17 | 4.23e-01 | 0.1096 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
| GO:1903311 | Colorectum | AD | regulation of mRNA metabolic process | 117/3918 | 288/18723 | 1.69e-14 | 4.23e-12 | 117 |
| GO:0043484 | Colorectum | AD | regulation of RNA splicing | 70/3918 | 148/18723 | 6.47e-13 | 1.16e-10 | 70 |
| GO:0006401 | Colorectum | AD | RNA catabolic process | 102/3918 | 278/18723 | 8.64e-10 | 6.76e-08 | 102 |
| GO:0044270 | Colorectum | AD | cellular nitrogen compound catabolic process | 147/3918 | 451/18723 | 3.35e-09 | 2.23e-07 | 147 |
| GO:0046700 | Colorectum | AD | heterocycle catabolic process | 145/3918 | 445/18723 | 4.37e-09 | 2.84e-07 | 145 |
| GO:0006402 | Colorectum | AD | mRNA catabolic process | 87/3918 | 232/18723 | 4.40e-09 | 2.84e-07 | 87 |
| GO:0034655 | Colorectum | AD | nucleobase-containing compound catabolic process | 133/3918 | 407/18723 | 1.56e-08 | 9.12e-07 | 133 |
| GO:0019439 | Colorectum | AD | aromatic compound catabolic process | 146/3918 | 467/18723 | 7.48e-08 | 3.84e-06 | 146 |
| GO:1901361 | Colorectum | AD | organic cyclic compound catabolic process | 153/3918 | 495/18723 | 8.23e-08 | 4.18e-06 | 153 |
| GO:0061013 | Colorectum | AD | regulation of mRNA catabolic process | 64/3918 | 166/18723 | 1.44e-07 | 6.59e-06 | 64 |
| GO:0043487 | Colorectum | AD | regulation of RNA stability | 63/3918 | 170/18723 | 9.17e-07 | 3.12e-05 | 63 |
| GO:0043488 | Colorectum | AD | regulation of mRNA stability | 59/3918 | 158/18723 | 1.50e-06 | 4.66e-05 | 59 |
| GO:00083801 | Colorectum | SER | RNA splicing | 123/2897 | 434/18723 | 3.84e-12 | 8.41e-10 | 123 |
| GO:00434841 | Colorectum | SER | regulation of RNA splicing | 49/2897 | 148/18723 | 7.02e-08 | 4.49e-06 | 49 |
| GO:19033111 | Colorectum | SER | regulation of mRNA metabolic process | 78/2897 | 288/18723 | 2.61e-07 | 1.43e-05 | 78 |
| GO:00442701 | Colorectum | SER | cellular nitrogen compound catabolic process | 99/2897 | 451/18723 | 1.46e-04 | 2.86e-03 | 99 |
| GO:00467001 | Colorectum | SER | heterocycle catabolic process | 97/2897 | 445/18723 | 2.20e-04 | 3.89e-03 | 97 |
| GO:19013611 | Colorectum | SER | organic cyclic compound catabolic process | 104/2897 | 495/18723 | 5.46e-04 | 7.63e-03 | 104 |
| GO:00346551 | Colorectum | SER | nucleobase-containing compound catabolic process | 88/2897 | 407/18723 | 5.53e-04 | 7.71e-03 | 88 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FASTK | SNV | Missense_Mutation | novel | c.1490C>G | p.Ser497Trp | p.S497W | Q14296 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A138-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| FASTK | SNV | Missense_Mutation | c.1298N>A | p.Leu433Gln | p.L433Q | Q14296 | protein_coding | deleterious(0.02) | probably_damaging(0.977) | TCGA-E9-A1ND-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD | |
| FASTK | SNV | Missense_Mutation | novel | c.94C>T | p.Pro32Ser | p.P32S | Q14296 | protein_coding | tolerated_low_confidence(0.1) | benign(0.011) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FASTK | SNV | Missense_Mutation | rs374560885 | c.1541N>T | p.Pro514Leu | p.P514L | Q14296 | protein_coding | tolerated(0.05) | benign(0.007) | TCGA-JW-A5VI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | topotecan | PD |
| FASTK | SNV | Missense_Mutation | rs774195132 | c.1627N>T | p.Arg543Cys | p.R543C | Q14296 | protein_coding | tolerated_low_confidence(0.25) | benign(0) | TCGA-A6-5657-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD |
| FASTK | SNV | Missense_Mutation | novel | c.1229N>A | p.Arg410His | p.R410H | Q14296 | protein_coding | tolerated(0.18) | benign(0.086) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| FASTK | SNV | Missense_Mutation | c.328N>T | p.Arg110Cys | p.R110C | Q14296 | protein_coding | tolerated_low_confidence(0.22) | benign(0) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FASTK | deletion | In_Frame_Del | novel | c.456_458delCTT | p.Phe153del | p.F153del | Q14296 | protein_coding | TCGA-5M-AAT4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | ||
| FASTK | deletion | Frame_Shift_Del | c.1224delN | p.Leu409CysfsTer14 | p.L409Cfs*14 | Q14296 | protein_coding | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |||
| FASTK | SNV | Missense_Mutation | novel | c.1411C>G | p.Arg471Gly | p.R471G | Q14296 | protein_coding | tolerated(0.39) | benign(0) | TCGA-2E-A9G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |